Vepsitamab

DB18211ExperimentalProtein Based Therapies

Vepsitamab: Overview.

Also known as
IMMUNOGLOBULIN, BISPECIFIC, ANTI-(HUMAN MUCIN 17) (HUMAN MONOCLONAL MUC17_CD3_ALT2 SINGLE-CHAIN VARIABLE FRAGMENT VH1-(GGGGS)3-VL1) FUSION PROTEIN WITH PEPTIDE LINKER (GGGGS) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) (HU

Resolves to

Compound
UNIIZR1EEO1ZLSCAS2413453-53-7

Which companies are running trials of Vepsitamab, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In